Adding chemotherapy, EGFR-TKIs, and some innovative agents (TMZ, Nitro, Endo, Enza, and Veli) to radiotherapy showed limited effects than radiotherapy alone for newly diagnosed BMs from EGFR/ALK-negative/unselected NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.